Generic Medicine Info
Indications and Dosage
Bladder spasms due to catheterisation, Dysuria, Urinary incontinence, urgency and frequency
Adult: 100-200 mg 3-4 times daily. May reduce when symptoms improve.
Child: ≥12 yr Same as adult dose.
May be taken with or without food.
Pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, GI haemorrhage, and obstructive uropathies of the lower urinary tract.
Special Precautions
Patient w/ suspected glaucoma (esp closed angle glaucoma); serious, uncontrolled, obstructive disorders of the lower urinary tract. Childn. Pregnancy and lactation.
Adverse Reactions
Nervous: Drowsiness, headache, vertigo, nervousness, mental confusion.
CV: Palpitation, tachycardia.
GI: Nausea, vomiting, dry mouth/throat, abdominal pain, constipation.
Resp: Reduced bronchial secretions.
Genitourinary: Dysuria.
Haematologic: Leucopenia, eosinophilia.
Ophthalmologic: Increased intraocular tension, accommodation disturbance, blurred vision, photophobia.
Dermatologic: Dryness, flushing, urticaria and other dermatoses.
Others: Hyperpyrexia.
Patient Counseling Information
This drug may cause drowsiness and blurred vision, if affected, do not drive or operate machinery.
Drug Interactions
Increased CNS effects w/ other sedative agents.
Food Interaction
Increased CNS effects w/ alcohol.
Description: Flavoxate is a tertiary amine w/ direct relaxant effect on smooth muscles through inhibition of phosphodiesterase, thereby reducing symptoms associated w/ bladder spasticity. It also has antimuscarinic effects.
Onset: 55 min.
Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: Approx 2 hr.
Metabolism: Rapidly metabolised, mainly to the active metabolite methyl flavone carboxylic acid (MFCA).
Excretion: Via urine (approx 50-60%, as MFCA).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Flavoxate, CID=3354, https://pubchem.ncbi.nlm.nih.gov/compound/Flavoxate (accessed on Jan. 21, 2020)

Store between 20-25°C. Protect from light.
MIMS Class
Drugs for Bladder & Prostate Disorders
ATC Classification
G04BD02 - flavoxate ; Belongs to the class of urinary antispasmodics.
Anon. Flavoxate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/03/2017.

Buckingham R (ed). Flavoxate Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2017.

Flavoxate Hydrochloride Tablet (Epic Pharma, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/03/2017.

Joint Formulary Committee. Flavoxate Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Flavoxate Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 06/03/2017.

Disclaimer: This information is independently developed by MIMS based on Flavoxate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
  • Cleanxate
  • Urispas
  • Uroxate
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in